FOLH1 and prostate cancer: First clinical studies have shown that PET/CT with 89Zr-labeled PSMA tracers reveal lesions suspicious for prostate cancer on late images that had been missed on conventional PSMA PET/CT with short-lived PSMA tracers [6,7,8].